专利号:US-2012177593-A1 优先权日:2009-07-20 标 题 :Synthesis of dendrimer conjugates 发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH 权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN 摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.
专利号:US-2003083352-A1 优先权日:2000-07-31 标 题 :Synthesis of imidazole intermediates 发明人:HELAL CHRISTOPHER J 权利人:PFIZER 摘要:The invention provides a method for synthesis of compounds of formula n n n wherein R 1 and R 19 are as defined. Compounds of formula 12 are useful as intermediates for synthesizing compounds having pharmacological activity inhibiting cdk5, cdk2, and GSK-3.
专利号:US-10005720-B2 优先权日:2013-04-05 标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same 发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L 权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL 摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.
专利号:WO-2022224090-A1 优先权日:2021-04-20 标题 :Method for the physical synthesis of metallic nanoparticles 发明人:Ã?VILA BERNAL ALBA GRACIELA; PÉREZ TABORDA JAIME ANDRÉS; LANZA BAYONA GUSTAVO ADOLFO 权利人:UNIV LOS ANDES 摘要:The present invention relates to a method for the physical synthesis of metallic nanoparticles, which comprises: (a) depositing a metallic film on a substrate of irregularly oriented salt crystal; and (b) heat-treating the metallic film deposited on the substrate until metallic nanoparticles form. This method makes it possible to obtain nanoparticles that are immobilised on a substrate and completely free of stabilising agents or surface ligands, in addition to nanoparticles in suspension or dry nanoparticles. The method also enables the production of nanoparticles having different sizes and diverse morphologies by adjusting the surface characteristics of the substrate, the characteristics of the metallic film and the thermal conditions established during the nanoparticle formation steps.
专利号:US-9315483-B2 优先权日:2007-09-13 标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof 发明人:JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT 权利人:CONCERT PHARMACEUTICALS INC 摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.
专利号:US-12234200-B2 优先权日:2019-04-16 标 题:Synthetic methods of preparing esketamine 发明人:CHEN CHENG YI 权利人:JANSSEN PHARMACEUTICA NV 摘要:The present invention is directed to methods for the asymmetric synthesis of esketamine. The present invention is further directed to key intermediates in the asymmetric esketamine synthesis. In one embodiment, the invention is an asymmetric synthesis of esketamine comprising the conversion of (S)-2′-chloro-2-methoxy-3,4,5,6-5 tetrahydro-[1, 1′-biphenyl]-3-yl carbamate to (S)-2′-chloro-1-isocyanato-6-methoxy-1,2,3,4-tetrahydro-1,1′-biphenyl.
1: Fonte C, Fatigoni S, Roila F. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol. 2015 Aug;95(2):214-21. doi: 10.1016/j.critrevonc.2015.02.010. Epub 2015 Mar 5. Review. doi: 10.1111/bcpt.12372. Epub 2015 Jan 28. Review. doi: 10.1155/2015/970730. Epub 2015 Jan 13. Review. 4: Luedecke D, Schöttle D, Karow A, Lambert M, Naber D. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs. 2015 Jan;29(1):41-6. doi: 10.1007/s40263-014-0216-9. Review. doi: 10.1007/s40264-014-0219-y. Review. Review. Russian. doi: 10.1517/14740338.2014.933804. Epub 2014 Jun 27. Review. doi: 10.1111/jphp.12209. Epub 2014 Jan 7. Review. doi: 10.1007/s00520-014-2138-y. Epub 2014 Feb 13. Review. Review. Review. 12: Zhao J, Ou J, Xue H, Liu L, Montgomery W, Treuer T. Clinical utility of orally disintegrating olanzapine in Chinese patients with schizophrenia: a review of effectiveness, patient preference, adherence, and other properties. Neuropsychiatr Dis Treat. 2014 Feb 19;10:355-9. doi: 10.2147/NDT.S39055. eCollection 2014. Review.
合成参考文献
参考文献:10.1192/bjp.187.6.537 摘要:Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005 Dec;187():537–43. doi: 10.1192/bjp.187.6.537. 参考文献:10.1097/00131746-200511001-00002 摘要:Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP; Expert Consensus Panel for Behavioral Emergencies 2005. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract. 2005 Nov;11 Suppl 1():5–108; quiz 110. doi: 10.1097/00131746-200511001-00002. 参考文献:10.2165/11203830-000000000-00000 摘要:Croxtall JD, Scott LJ. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs. 2010 Mar;24(3):245–62. doi: 10.2165/11203830-000000000-00000. 参考文献:10.4088/jcp.08m04411gry 摘要:Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, Dellva MA, Carlson JL, Cavazzoni PA, Baker RW. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry. 2010 Apr;71(4):433–41. doi: 10.4088/jcp.08m04411gry.